SCHEMBL6801293

SCHEMBL6801293

CCN(Cc1ccccc1)C(=O)[C@H](Cc1ccc(OC)cc1)Nc1nc2c(Br)cc(CN(Cc3ccccc3)C(=O)O)c(C)c2c(=O)o1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 5/20 0.41
TSHR P16473 2/20 0.36
PTPN2 P17706 1/20 0.35
PTPN1 P18031 1/20 0.35
LMNA P02545 2/20 0.34
PIN1 Q13526 1/20 0.34
TSPO P30536 1/20 0.34
BAX Q07812 1/20 0.34
ALDH1A1 P00352 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
MEN1 O00255 1/20 0.34
ALOX12 P18054 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
NPC1 O15118 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6804618 0.93 ELANE (0.41) ELANETSHRLMNAPIN1TSPO
SCHEMBL6805137 0.93 ELANE (0.39) ELANETSHRPTPN2PTPN1LMNA
SCHEMBL6497577 0.93 ELANE (0.40) ELANETSHRPTPN2PTPN1LMNA
SCHEMBL6801336 0.92 ELANE (0.38) ELANETSHRPTPN2PTPN1LMNA
SCHEMBL7445664 0.91 ELANE (0.40) ELANETSHRPTPN2PTPN1LMNA
SCHEMBL6802037 0.87 ELANE (0.46) ELANELMNAALDH1A1L3MBTL1MEN1
SCHEMBL6801500 0.86 ELANE (0.42) ELANEMEN1KMT2ANPC1HPGD
SCHEMBL6505448 0.86 ELANE (0.40) ELANETSHRLMNAPIN1TSPO
SCHEMBL6800996 0.86 ELANE (0.41) ELANELMNAALDH1A1NPC1HPGD
SCHEMBL6806153 0.84 ELANE (0.39) ELANEL3MBTL1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6683077-B2 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS G.D. SEARLE & CO. 2004-01-27 US disclosed
US-20030022895-A1 2-Amino-benzoxazinones for the treatment of viral infections G.D. SEARLE & CO. 2003-01-30 US disclosed
US-6380189-B1 FOR TREATING HERPES-RELATED DISORDERS G.D. SEARLE & CO. 2002-04-30 US disclosed
EP-0828721-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1998-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022895-A1 2-Amino-benzoxazinones for the treatment of viral infections IFNAR1, IL4I1, HAX1 ELANE 2176/4885TSHR 1583/4885PTPN2 1339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.